Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pharmstandard OJSC

www.pharmstd.ru

Latest From Pharmstandard OJSC

Deal Watch: Bayer/CRISPR Link-up Highlights Spate Of Deals At Year-End

Lilly is the latest established biopharma to license Halozyme's EXTENZE subcutaneous delivery technology. Mallinckrodt pays $175m up front to The Medicines Co. for a trio of topical hemostasis drugs.

BioPharmaceutical Deals

Deals Shaping The Medical Industry, September 2015

Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced in August 2015.

BioPharmaceutical Medical Device

Deal Watch: AbbVie Pays Highest Price Yet Seen For Priority Review Voucher

Depomed deems increased buyout offer from Horizon as insufficient, possibly leaving Horizon to consider alternative acquisitions. Valeant will pay $1bn to acquire Sprout and its just approved female sexual desire disorder drug Addyi.

BioPharmaceutical Deals

Venture Funding Deals, May 2015

Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Venture Funding Deals column provides a comprehensive monthly review of emerging life science companies that have received venture funding, including companies within the In Vitro Diagnostics, Medical Devices, and Pharmaceuticals sectors. This month’s column covers deals announced March through April 2015.

BioPharmaceutical Medical Device
See All

Company Information

  • Industry
  • Pharmaceuticals
  • Therapeutic Areas
  • Non-Specific
  • Alias(es)
  • OJSC Pharmstandard
  • Biovit LLC
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • Europe
      • Eastern Europe
        • Russia
  • Parent & Subsidiaries
  • Pharmstandard OJSC
  • Senior Management
  • Vladimir Chupikov , CEO
    Marina Markova , CFO
  • Contact Info
  • Pharmstandard OJSC
    Phone: 495 970 00 30
    5 ‘B’ Likhachevsky proezd
    Dolgoprudny, Moscow Region, 141700
    Russia
Advertisement
Advertisement
UsernamePublicRestriction

Register